Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

NCT05805605 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.

NCT NCT05805605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05805605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Lead sponsor
Masonic Cancer Center, University of Minnesota
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2023
Completion date
October 22, 2028
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, acute myelogenous leukemia, biphenotypic acute leukemia, burkitt lymphoma, chronic myelogenous leukemia, follicular lymphoma, leukemia, myeloid, marginal zone lymphoma, myelodysplastic syndrome with excess blasts-1, myelodysplastic syndromes, myelofibrosis, myeloproliferative neoplasm, plasma cell leukemia, prolymphocytic leukemia, relapsed chronic lymphocytic leukemia, relapsed t-cell lymphoma, small lymphocytic lymphoma, undifferentiated leukemia